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I appreciate this opportunity to respond to comments by Mahan and colleagues [1] on our 
recent review of US estimates of medical costs attributable to venous thromboembolism 
(VTE) [2]. Prior to the publication of that article, Dr. Mahan, provided helpful comments on 
our draft manuscript. He and his colleagues have made important contributions to raising 
awareness of the economic burden of VTE.
I would like to clarify that our article was not intended as a comprehensive cost-of-illness 
(COI) study. Our article sought to generate consensus estimates of direct medical costs 
attributable to VTE in order to project benefits of VTE prevention in the United States. This 
study, initiated during 2011–2013, was one part of a health economics research agenda on 
VTE for the Division of Blood Disorders at the US Centers for Disease Control and 
Prevention (CDC). Other studies were initiated to provide information to improve estimates 
of the indirect costs of VTE, including a cohort study in Norway of permanent work 
disability secondary to incident VTE [3].
In order to facilitate the inclusion of productivity costs in COI studies, I have published 
“human capital” estimates of annual and lifetime present values of market and nonmarket 
productivity in the United States [4]. Some economists argue that the conventional human 
capital approach overstates the economic impact of removing people from the work force 
and recommend a “friction cost” method that only includes the transition cost of replacing a 
disabled or deceased worker with a new worker [5].
The choice of which costs to include in a given COI analysis depends on the purpose of the 
study. Many COI estimates are used to inform cost-effectiveness analyses (CEAs) of 
interventions. For CEAs, it is generally recommended that only direct costs be included, 
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although some guidelines call for the inclusion of productivity costs in CEAs from the 
societal perspective [6]. Numerous CEAs of anticoagulant use for VTE management or 
prevention have been published, almost all of which have taken the healthcare perspective 
and used estimates of direct medical costs without productivity costs.
The authors assert that CDC “recently acknowledged that indirect costs should be included 
in cost-of-illness models.” That assertion is incorrect; CDC has never issued guidance on 
which costs should be included in COI analyses. The reference cited provides no support. A 
presentation on COI methods hosted on the CDC website notes that COI studies can be 
either restricted to medical costs or include both direct and indirect costs. COI studies from 
the healthcare perspective are restricted to medical costs, whereas societal-perspective COI 
studies typically include both direct and indirect costs. Both approaches are acceptable, with 
a slight majority of COI studies including indirect costs [7].
The second “key disagreement” is whether incidence-based COI estimates are preferred to 
prevalence-based estimates for assessing the value of VTE prevention. A prevalence-based 
cost estimate indicates costs for persons alive in 2015 who had ever been diagnosed with a 
condition, either in 2015 or in previous years, which resulted in medical costs, disability, or 
death during 2015. An incidence-based cost estimate, in contrast, calculates the present 
value of expected costs during 2015 and future years resulting from new cases during 2015, 
including future complications from those cases [8]. In other words, prevalence-based COI 
studies calculate present-year costs for cases occurring in previous years or the present year, 
and incidence-based COI studies start with new cases and look forward to calculate expected 
costs in present and future years. The implication is that a prevalence-based cost estimate for 
VTE assesses the hypothetical annual cost savings that could have been realized if no one 
alive in the present year had ever experienced VTE, whereas a forward-looking incidence-
based cost estimate predicts how much could be saved by preventing new cases of VTE.
Mahan et al. [1] assert that “evaluation of prevalence versus incident new cases is a more 
plausible approach to determine the burden of disease and financial impact of complications 
such as PTS and CTPH.” Prevalence-based COI estimates are indeed commonly used for 
burden of disease calculations, in part because they are relatively straightforward to calculate 
[8–10]. However, if the intent is to estimate the financial impact of preventing new cases of 
VTE and their downstream complications, forward-looking incidence-based cost models are 
needed [8].
In conclusion, our article was not intended as a comprehensive COI analysis, but rather to 
synthesize US estimates of medical costs associated with incident cases of VTE [2]. Indirect 
costs are important to societal-perspective COI studies, and more research is needed to 
quantify the productivity losses resulting from VTE. The newly published study linking 
incident VTE to subsequent receipt of disability pensions in Norway [3] represents one 
contribution to that goal.
COI studies are conducted for different purposes. In order to inform economic evaluations of 
VTE prevention, forward-looking incidence-based models are needed. Whether indirect 
costs are relevant to include in a specific study depends on the study purpose, and COI 
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studies may be appropriately restricted to medical costs [10]. The choices involved in setting 
up COI models can be complex, and readers should seek to understand the appropriate uses 
of each type of cost model.
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